Our study shows that concurrent delivery of SB11285, a cyclic dinucleotide-based STING agonist that is intravenously available and has recently begun evaluation in clinical trials, improves the efficacy of radiation therapy in HNSCC tumors. This evidence concerns the gene STING1 and head and neck squamous cell carcinoma.